How to escape the cancer attractor: rationale and limitations of multi-target drugs

Sui Huang1, Stuart Kauffman

  • 1Institute for Systems Biology, Seattle WA, USA. sui.huang@systemsbiology.org

Insights

Targeting cancer cells requires a dynamic approach beyond single pathways. Understanding global network dynamics and quasi-potential landscapes can guide therapies to overcome resistance and recurrence.

Area of Science:

  • Systems Biology
  • Cancer Research
  • Computational Biology

Background:

  • Target-selective cancer therapies face limitations due to resistance and recurrence.
  • Current strategies often focus narrowly on individual causal pathways, neglecting network complexity.

Purpose of the Study:

  • To review a formal framework of global network dynamics for cancer therapy.
  • To explore how quasi-potential landscapes and least-action-path theory can guide multi-target drug development.

Main Methods:

  • Conceptual review of network dynamics as attractor states in gene regulatory networks.
  • Application of quasi-potential landscape and least-action-path theory to identify therapeutic targets.
  • Discussion of dynamic non-genetic heterogeneity in cancer cell populations.

Main Results:

  • Cancer cells can be conceptualized as high-dimensional attractor states within gene regulatory networks.
  • Therapy can be viewed as a perturbation to exit cancer attractors and re-enter normal attractors.
  • Identifying multiple network nodes for concerted targeting is crucial for effective therapy.

Conclusions:

  • Global network dynamics provide a more encompassing framework for understanding and treating cancer.
  • Dynamic heterogeneity necessitates adaptive therapeutic strategies beyond targeting an 'average' cancer cell.
  • Future cancer therapies should integrate network dynamics and heterogeneity to overcome resistance.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...